Abstract
In treatment trials, as well as in clinical practice, a number of individuals with depression fail to respond to medications with established antidepressant properties. The presence of such non-responders has been considered as indicative of inter-individual variability in treatment responsiveness, but disparate outcomes between individuals could also be due to other factors, such as inter-individual differences in disease severity and spontaneous improvement (1). To address this issue, recent studies (1,2) have compared variability (specifically standard deviations, SDs) between groups administered active treatment and placebo across trials. When no differences in variability have been found, this has been quoted as an argument against antidepressants being effective or against the value of precision medicine in depression (1).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
